Compare Gilead Sciences, Inc. (GILD) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Under Armour Inc Class A — how do they compare? Gilead Sciences, Inc. trades at $134.76 (market cap $163.51B), while Under Armour Inc Class A trades at $7.05 (market cap $2.89B). The key difference: Gilead Sciences, Inc. is far larger — about 56.6× Under Armour Inc Class A's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| GILD | UA | |
|---|---|---|
Market Cap | $163.51B | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $7.88 |
52-Week Low | $108.22 | $3.96 |
Enterprise Value | $178.05B | $4.52B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Under Armour (UA) trades at $6.915, up 6.88% today, with a bullish technical signal from moving averages and oscillators. The company reported a net loss of -$201.27 million in 2025, with a negative net income margin of -9.98%, though it beat earnings expectations in two of the last three quarters. Recent news includes a Dodge collaboration and a 1.2 million share purchase by Prem Watsa's Fairfax Financial, signaling institutional interest amid ongoing business restructuring.
The outlook remains challenged by declining revenues and persistent losses, but low P/S of 0.58 and analyst buy ratings (40.3%) suggest potential if turnaround efforts gain traction. Key risks include execution missteps, competitive pressure, and further revenue erosion, requiring careful monitoring of 2027 guidance for sustainable recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
